CRJ Pharmacy, Inc. and YPM Total Care Pharmacy, Inc.; Revocation of Registrations, 30846-30849 [E7-10624]
Download as PDF
30846
Federal Register / Vol. 72, No. 106 / Monday, June 4, 2007 / Notices
Nolte Drive, West Deptford, New Jersey
08066, made application by letter to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
II:
Schedule
Drug
Methadone (9250) ..........................
Methadone Intermediate (9254) .....
II
II
The company plans to use the
Methadone Intermediate to produce the
Methadone HCL for sale to its customers
who are final dosage manufacturers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Johnson Matthey Inc. to manufacture
the listed basic class of controlled
substance is consistent with the public
interest at this time. DEA has
investigated Johnson Matthey Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: May 29, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–10692 Filed 6–1–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 07–19]
rwilkins on PROD1PC63 with NOTICES
CRJ Pharmacy, Inc. and YPM Total
Care Pharmacy, Inc.; Revocation of
Registrations
This is a consolidated proceeding
involving two pharmacies under
common ownership. On February 2,
2007, I issued an Order to Show Cause
and Immediate Suspension of DEA
Certificates of Registration, BC9458539,
issued to CRJ Pharmacy, Inc., and
BY9713276, issued to YPM Total Care
Pharmacy, both of Lakeland, Florida. I
immediately suspended each
VerDate Aug<31>2005
20:34 Jun 01, 2007
Jkt 211001
Respondent’s registration based on my
preliminary finding that they had
‘‘diverted and continue to divert
massive amounts of controlled
substances in violation’’ of federal law
‘‘thereby creating an imminent danger to
public health or safety.’’ Show Cause
Order at 5. The Show Cause Order
further sought the revocation of each
Respondent’s registration on the ground
that its continued registration would be
‘‘inconsistent with the public interest.’’
Id. at 1 (citing 21 U.S.C. 823(f) &
824(a)(4)).
With respect to CRJ Pharmacy, the
Show Cause Order alleged that it was
the fourteenth largest retail purchaser of
hydrocodone-combination products in
the State of Florida, and that ‘‘[f]rom
January through November 2006, CRJ
purchased 1,416,320 dosage units of
brand name and generic hydrocodone
combination products,’’ a schedule III
controlled substance. Id. The Show
Cause Order further alleged that on
March 30, 2006, DEA investigators had
inspected CRJ and determined that it
filled controlled substance orders
placed through a Web site,
yourpainmanagement.com; that the
orders were for persons throughout the
United States; and that the orders were
authorized by only two physicians. Id.
at 2. According to the allegations, one of
the physicians was licensed to practice
only in Florida; the other was licensed
only in Minnesota. Id.
The Show Cause Order further alleged
that on January 22, 2007, DEA
investigators executed an administrative
search warrant at CRJ and obtained
records showing that between July 3,
2006, and January 22, 2007, CRJ had
‘‘filled approximately 19,223 controlled
substance drug orders and shipped them
to customers throughout the United
States.’’ Id. The Show Cause Order also
alleged that these prescriptions were
authorized by physicians located in
Texas, Wisconsin, Puerto Rico, New
York, California, Kansas, and Florida,
for persons who did not reside in the
same States as the physicians, that the
prescriptions were disproportionately
for ‘‘one or two types of highly addictive
and abused controlled substances,’’ that
‘‘CRJ filled large quantities of
prescriptions per day, per physician,’’
and thus CRJ knew or should have
known that the prescriptions it
dispensed ‘‘were not issued ‘for a
legitimate medical purpose by an
individual practitioner acting in the
usual course of his professional
practice.’ ’’ Id. at 4 (quoting 21 CFR
1306.04(a)).
The Show Cause Order alleged that
CRJ’s owner, Mr. Chris Larson, had
admitted to investigators that he owned
PO 00000
Frm 00104
Fmt 4703
Sfmt 4703
bestrxcare.com. Id. at 2. According to
the Show Cause Order, Mr. Larson told
investigators that persons seeking
controlled substances completed an online questionnaire and then faxed their
medical records to bestrxcare.com,
where they were scanned into a
database for review by either a
physician or a physician’s assistant
(PA). Id. Mr. Larson allegedly told
investigators that if the records were
‘‘ok,’’ a physician or a PA would then
consult with the customer by telephone.
Id. According to the Show Cause Order,
after the customer had paid the Web site
and the phone consultation was
completed, a ‘‘prescription’’ was issued
which CRJ then downloaded from the
Internet and dispensed. Id.
The Show Cause Order further alleged
that a physician employed by Larson
had admitted to investigators that
Larson was using his DEA ‘‘license for
pain pills.’’ Id. at 3. According to the
Show Cause Order, the physician
further admitted that ‘‘he does not speak
with any of the Internet customers or
their primary care physicians,’’ and that
he ‘‘does not diagnose the Internet
customers or provide after care services
for the Internet customers.’’ Id.
With respect to YPM, the Show Cause
Order alleged that it was dispensing
controlled substances that were ordered
through another Web site,
yourpainmanagment.com, which was
also owned by Larson. Id. at 4. The
Show Cause Order alleged that on
August 17, 2005, Larson stated to DEA
investigators that a person could order
controlled substances for pain
management through this Web site by
completing a form on which they
provided their name, address, billing
information, general biographic details
and medical complaint. Id. Larson
allegedly also told investigators that the
customers would then fax their medical
records to the Web site where they were
then reviewed by a PA; if the records
appeared ‘‘in order,’’ either a physician
or the PA would conduct a telephone
consultation with the customer. Id. The
Show Cause Order further alleged that
during this interview, one of Larson’s
employees told DEA investigators that
the Web site does not order further
testing of its customers and does not
contact the physicians named on the
customers’ medical records. Id.
The Show Cause Order also alleged
that from May 2006 through November
2006, YPM had purchased 841,800 units
of hydrocodone-combination products.
Id. Relatedly, the Show Cause Order
alleged that YPM records showed that it
had dispensed 17,336 controlled
substance orders to internet customers
throughout the United States and that
E:\FR\FM\04JNN1.SGM
04JNN1
rwilkins on PROD1PC63 with NOTICES
Federal Register / Vol. 72, No. 106 / Monday, June 4, 2007 / Notices
98 percent of the orders were authorized
by three physicians. Id. The Show Cause
Order further alleged that two of these
physicians were licensed to practice
medicine in Florida; moreover, between
June 1, 2006, and January 19, 2007, the
third physician, who was licensed in
Minnesota, had authorized 15,050
orders. Id. The Show Cause Order thus
alleged that YPM ‘‘knew or should have
known that the ‘prescriptions’ [it]
dispensed were not issued ‘for a
legitimate medical purpose by an
individual practitioner acting in the
usual course of his professional
practice’’’ and violated federal law. Id.
at 4 (quoting 21 CFR 1306.04(a)).
On February 5, 2007, both CRJ and
YPM were served with the Order to
Show Cause and Immediate Suspension
of Registrations. On February 22, 2007,
both Respondents, who were
represented by the same counsel,
requested a hearing on the allegations.
The matters were assigned to
Administrative Law Judge (ALJ) Mary
Ellen Bittner.
On March 12, 2007, the Government
moved for summary disposition. The
basis for the Government’s motion was
that Respondents had closed their
businesses on February 12, 2007, and
had ‘‘transferred all prescription
records, inventory, and required DEA
records to other DEA registrants.’’ Gov.
Mot. for Summ. Disp. at 1. The
Government’s motion further asserted
that on February 27, 2007, Respondent
CRJ had surrendered its Florida Board of
Pharmacy License to the Florida Board
of Pharmacy. Id. The Government
further asserted that Respondent YPM
had ‘‘signified its intent to surrender its
Florida Board of Pharmacy License in
its letter to DEA dated February 22,
2007.’’ Id. at 2. The Government thus
asserted that both ‘‘Respondents are
currently without authority under
Florida law to dispense controlled
substances’’ and therefore are not
entitled to maintain their DEA
registrations. Id.
In support of its motion, the
Government attached copies of letters
from both YPM (dated Feb. 27, 2007)
and CRJ (dated Feb. 28, 2007) to the
DEA Miami Office; each letter advised
that the pharmacy had closed, that it
was in the process of surrendering its
state license, and sought permission to
act as a one-time wholesaler to sell the
controlled substances (which apparently
were still in their possession) to another
pharmacy. See Appendices I & II to Gov.
Mot. The Government also attached a
copy of the letter from CRJ to the Florida
Board of Pharmacy, by which it
surrendered its state license. See
Appendix III to Gov. Mot. The
VerDate Aug<31>2005
20:34 Jun 01, 2007
Jkt 211001
Government’s submission did not,
however, include a similar letter from
YPM.
Respondent did not oppose this
motion. Response to Gov. Motion for
Summ. Disp. at 1. However, on March
16, 2007, the Government had also filed
a motion to supplement the motion for
summary disposition. The Government
based its motion on my decision in
William R. Lockridge, M.D., 71 FR
77,791 (2006). In Lockridge, I reviewed
the propriety of an immediate
suspension in a case in which the
Respondent’s registration had expired,
in part, because of the collateral
consequences which attached with the
issuance of the suspension. The
Government thus moved to submit
several affidavits of DEA investigators to
support ‘‘the basis for the immediate
suspensions.’’ Gov. Mot. to Supp. at 1.
Thereafter, on March 19, 2007, the
ALJ afforded Respondents the
opportunity to respond to the
Government’s motion by April 2, 2007.
Subsequently, on March 22, 2007, the
ALJ granted the Government’s motion
for summary disposition to the extent it
sought the revocation of Respondents’
DEA registrations on the ground that
CRJ and YPM were without authority
under Florida law to handle controlled
substances and therefore were not
entitled to maintain their DEA
registrations. ALJ Dec. at 3. The ALJ
thus recommended that Respondents’
registrations be revoked. Id.
The ALJ also granted the
Government’s motion to supplement its
original motion for summary disposition
and submit into the record the two
affidavits. The ALJ, however, also
afforded Respondents the opportunity to
submit additional documents including
affidavits.1
On April 2, 2007, Respondents filed
their response which vigorously
opposed the Government’s motion.
Respondents contended that there is
‘‘no dispute’’ that they ‘‘can no longer
hold DEA registrations.’’ Response at 3.
Respondents maintained, however, that
the Government’s reliance on Lockridge
was misplaced because in there, a full
hearing had been held and ‘‘[m]ootness
was implicated only when the
respondent’s registration expired after
the hearing.’’ Id. at 4.
Respondents further argued that
‘‘[t]he Government itself has claimed
that this case is moot and therefore no
hearing should be held,’’ and that this
precludes a ‘‘ruling on the immediate
suspension as the Government seeks.’’
1 The ALJ did not, however, rule on the
Government’s alternative basis for summary
disposition.
PO 00000
Frm 00105
Fmt 4703
Sfmt 4703
30847
Id. Respondents also contended that
because of the collateral consequences
that attach with the issuance of an
immediate suspension, ‘‘to the extent
the Deputy Administrator seeks to
uphold the suspension, CRJ and YPM
have a right to a hearing.’’ Id.
Respondents thus maintained that
granting the Government’s
supplemental motion would ‘‘violate
[their] hearing rights’’ because the
Government’s affidavits are
‘‘conclusory’’ and cannot support the
‘‘factual findings’’ sought by the
Government. Id. at 4–5 (citing 21 CFR
1316.41). Finally, Respondent
contended that Lockridge ‘‘does not, and
cannot, hold that a decision on the
merits may issue after a summary
disposition.’’ Id. at 5. Respondents did
not, however, submit any affidavits of
their own.
Neither party filed exceptions to the
ALJ’s decision. Thereafter, the ALJ
forwarded the record to me for final
agency action. Having considered the
record as a whole, I hereby issue this
final order. I adopt the ALJ’s
recommendation that each Respondent’s
registration be revoked on the ground
that it no longer has authority to handle
controlled substances in the State of
Florida and thus is not entitled to hold
a DEA registration in that State. I further
conclude that my decision in Lockridge
is not controlling and that the issue of
the validity of the immediate
suspensions is now moot because each
Respondent has surrendered its Florida
pharmacy license and closed its
business. Moreover, neither the
Government nor Respondents have
pointed to any non-speculative
collateral consequence which a ruling
on the merits of the immediate
suspension order would resolve. I make
the following findings.
Findings
On April 21, 2006, Respondent YPM
Total Care Pharmacy, Inc., was issued
DEA Certificate of Registration,
BY9713276, as a retail pharmacy, with
an expiration date of May 31, 2009. On
some date not specified in the record,
Respondent CRJ Pharmacy, Inc., was
issued DEA Certificate of Registration,
BC9458539, with an expiration date of
August 31, 2008.
On February 7, 2007, DEA
investigators served both YPM Total
Care Pharmacy, Inc., and CRJ Pharmacy,
Inc., with the above described Order to
Show Cause and Immediate Suspension
of Registration. Shortly thereafter, on
February 12, 2007, YPM closed its
pharmacy. Moreover, on February 26,
2007, YPM transferred its prescription
records to another DEA registrant, and
E:\FR\FM\04JNN1.SGM
04JNN1
30848
Federal Register / Vol. 72, No. 106 / Monday, June 4, 2007 / Notices
on February 28, 2007, YPM transferred
its records and inventory of controlled
substances (with the Agency’s approval)
to that registrant. YPM subsequently
surrendered its Florida Pharmacy
License. I take official notice of the
online records of the Florida
Department of Health which confirm
that YPM Total Care Pharmacy has
closed.2
According to the record, on February
12, 2007, CRJ Pharmacy, Inc., also
closed its pharmacy. On February 26,
2007, CJR transferred its prescription
records to another DEA registrant, and
on February 28, 2007, transferred its
records and inventory of controlled
substances to that registrant. CJR
subsequently surrendered its Florida
Pharmacy License. I also take official
notice of the online records of the
Florida Department of Health which
confirm that CRJ Pharmacy has closed.
Discussion
rwilkins on PROD1PC63 with NOTICES
Under the Controlled Substances Act,
a practitioner must be currently
authorized to handle controlled
substances in ‘‘the jurisdiction in which
[it] practices’’ in order to maintain its
DEA registration. See 21 U.S.C. 802(21)
(‘‘[t]he term ‘practitioner’ means a * * *
pharmacy * * * licensed, registered, or
otherwise permitted, by * * * the
jurisdiction in which [it] practices
* * * to * * * dispense a controlled
substance in the course of professional
practice’’). See also id. section 823(f)
(‘‘The Attorney General shall register
practitioners * * * if the applicant is
authorized to dispense * * * controlled
substances under the laws of the State
in which [it] practices.’’). As numerous
agency orders have held, ‘‘a registrant
may not hold a DEA registration if it is
without authority under the laws of the
state in which it does business.’’ Bourne
Pharmacy, Inc., 72 FR 18273, 18274
(2007) (quoting Oakland Medical
Pharmacy, 71 FR 50100, 50102 (2006)).
Accord Rx Network of South Florida,
LLC, 69 FR 62,093 (2004); Wingfield
Drugs, Inc., 52 FR 27,070 (1987).
Each Respondent having surrendered
its State license, neither now disputes
‘‘that summary disposition and
2 Under the Administrative Procedure Act (APA),
an agency ‘‘may take official notice of facts at any
stage in a proceeding-even in the final decision.’’
U.S. Dept. of Justice, Attorney General’s Manual on
the Administrative Procedure Act 80 (1947) (Wm.
W. Gaunt & Sons, Inc., Reprint 1979). In accordance
with the APA and DEA’s regulations, Respondent
is ‘‘entitled on timely request, to an opportunity to
show to the contrary.’’ 5 U.S.C. 556(e); see also 21
CFR 1316.59(e). Respondent can dispute these facts
by filing a properly supported motion for
reconsideration within fifteen days of service of this
order, which shall begin on the date this order is
mailed.
VerDate Aug<31>2005
20:34 Jun 01, 2007
Jkt 211001
revocation are appropriate.’’ Response
to Gov. Mot. to Supplement at 3.
Respondents do, however, object to the
Government’s submission of the two
affidavits and my ruling on the merits
of the immediate suspension.
Respondents assert that Lockridge is
distinguishable because there, a full
evidentiary hearing had been held, and
here, no such hearing has been held.
Respondents further argue that the
validity of the immediate suspensions is
now a moot issue although they
contend—inconsistently—that they are
entitled to a hearing ‘‘before bearing the
adverse collateral consequences’’ that
would arise were I to issue a ruling
upholding the immediate suspension
orders.
I conclude that Lockridge is not
controlling and that the issue of the
validity of the immediate suspensions
in this case is now moot. It is
fundamental that the issuance of an
immediate suspension imposes a
deprivation of a property interest which
gives rise to the protections of the Due
Process Clause. See, e.g., FDIC v.
Mallen, 486 U.S. 230, 240 (1988).
Subsequent events may nonetheless
make clear that there is no longer a live
controversy between the parties even
when the Government has yet to
provide the constitutionally required
process. Cf. City News and Novelty, Inc.,
v. City of Waukesha, 531 U.S. 278
(2001).
In Lockridge, I held that the
proceeding was not moot
notwithstanding that the practitioner
had allowed his registration to expire
following the hearing and there was no
existing registration to act upon. In so
holding, I relied on several factors.
These included the collateral
consequences that attached with the
issuance of the immediate suspension,
in particular the harm to the
practitioner’s reputation, and the
additional disability imposed by the
Agency’s requirement to report the
suspension on any subsequent
application for a DEA registration.
I also noted that the practitioner had
not moved to dismiss the proceeding on
mootness grounds and that he had
submitted no evidence showing that he
‘‘intend[ed] to permanently cease the
practice of medicine.’’ 71 FR at 77797.
I thus concluded that Respondent might
apply for a new registration and seek to
engage in the same practices which had
prompted the immediate suspension.
Thus, it was not ‘‘ ‘absolutely clear that
[the practitioner’s] allegedly wrongful
behavior could not reasonably be
expected to recur.’ ’’ Id. (quoting Friends
of the Earth, Inc., v. Laidlaw Env. Servs.,
PO 00000
Frm 00106
Fmt 4703
Sfmt 4703
Inc., 528 U.S. 167, 189 (2000) (other
quotations and citations omitted)).3
Here, by contrast, the record
establishes that each Respondent has
not only surrendered its State license,
but has also gone out of business.
Moreover, in contrast to the registrant in
Lockridge, each Respondent has not
only engaged in affirmative acts
showing that it was ending its business
activities, it has also expressly
communicated these facts to the
Agency. Relatedly, neither Respondent
opposes the revocation of its registration
nor seeks to litigate the validity of the
suspension orders.
Finally, neither Respondent has
asserted that it plans to re-enter the
business of pharmacy at some future
date. The speculative possibility that
either Respondent will seek a new
registration at some point in the future
is not enough to conclude that sufficient
collateral consequences exist to render
the issue of the suspension orders’
validity a live dispute. See, e.g., City
News, 531 U.S. at 285; Spencer v.
Kemna, 523 U.S. 1, 16 (1998). Indeed,
were either Respondent to apply for a
new registration in the future, it would
nonetheless be required to disclose on
its application the revocation being
ordered below. Under these
circumstances, the suspension orders
impose on Respondents no additional
consequence beyond what they will be
required to disclose because of the
revocations of their registrations.4
Accordingly, the issue is now moot.
Order
Pursuant to the authority vested in me
by 21 U.S.C. 824, as well as 28 CFR
0.100(b) & 0.104, I hereby order that
DEA Certificate of Registration,
BC9458539, issued to CRJ Pharmacy,
Inc., and DEA Certificate of Registration,
BY9713276, issued to YPM Total Care
Pharmacy, Inc., be, and they hereby are,
revoked. I further order that pending
applications for renewal or modification
of either registration be, and they hereby
are, denied. This order is effective July
5, 2007.
3 I also noted the extensive resources committed
by both parties in litigating the case and the
potential prejudice to the public interest were I to
dismiss the proceeding without making findings.
4 Finally, in this proceeding, the Government
apparently did not place under seal the controlled
substances possessed by either Respondent at the
time of the suspensions. See 21 U.S.C. 824(f).
Accordingly, title to the controlled substances is not
a collateral issue which would be resolved in this
proceeding.
E:\FR\FM\04JNN1.SGM
04JNN1
Federal Register / Vol. 72, No. 106 / Monday, June 4, 2007 / Notices
Dated: May 21, 2007.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E7–10624 Filed 6–1–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 06–4]
rwilkins on PROD1PC63 with NOTICES
Trinity Health Care Corp., D/B/A/
Oviedo Discount Pharmacy;
Affirmance of Immediate Suspension
On August 19, 2005, I, the Deputy
Administrator of the Drug Enforcement
Administration, issued an Order to
Show Cause and Immediate Suspension
of Registration to Trinity Healthcare
Corporation, d/b/a/ Oviedo Discount
Pharmacy (Respondent) of Oviedo,
Florida. The Order immediately
suspended Respondent’s Certificate of
Registration, BT2863668, as a retail
pharmacy, based on my preliminary
finding that Respondent was filling
large quantities of prescriptions for
controlled substances that were issued
through an internet site, iPharmacy.MD,
by physicians who did not have a
legitimate doctor-patient relationship
with the individuals who ordered the
drugs. See Show Cause Order at 5–10.
Based on my preliminary finding that
Respondent was ‘‘responsible for the
diversion of large quantities of
controlled substances,’’ and that its
participation in this scheme ‘‘invites the
fraudulent procurement of controlled
substances on a vast scale,’’ I concluded
that Respondent’s continued registration
pending these proceedings ‘‘would
constitute an imminent danger to the
public health and safety,’’ and therefore
immediately suspended its registration.
Id. at 10.
More specifically, the Show Cause
Order alleged that Respondent was
filling prescriptions for phentermine, a
schedule IV controlled substance, which
were issued to the customers of
iPharmacy.MD by Richard Carino, a
physician located in Port Richey,
Florida. Id. at 5. The Show Cause Order
alleged that Dr. Carino issued
prescriptions for phentermine to
persons located ‘‘throughout the
country’’ based solely on a
questionnaire. Id. The Show Cause
Order further alleged that DEA
investigators interviewed various
individuals who had been prescribed
controlled substances by Dr. Carino;
each of these persons stated that they
were not patients of Dr. Carino and had
not provided him with their medical
records. Id. at 6.
VerDate Aug<31>2005
20:34 Jun 01, 2007
Jkt 211001
The Show Cause Order also alleged
that on May 6, 2004, DEA investigators
conducted an inspection of Respondent
during which they obtained its
prescription records for the period
January 1 through May 6, 2004. Id. at 7.
The Show Cause Order alleged that
between January and May 5, 2004,
Respondent had filled 2,196 internet
prescriptions for phentermine issued by
Dr. Carino to persons located
throughout the United States. Id. at 7–
8.
Finally, the Show Cause Order alleged
that on April 15, 2005, a DEA Special
Agent (S/A) had accessed the
iPharmacy.MD Web site, completed a
questionnaire, and ordered 90 tablets of
phentermine. Id. at 9. The Show Cause
Order further alleged that on April 21,
2005, the S/A received a bottle of
phentermine which had been filled by
Respondent.
Respondent, through its counsel,
requested a hearing. The matter was
assigned to Administrative Law Judge
(ALJ) Mary Ellen Bittner, who
conducted a hearing on May 30 through
June 2, 2006, in Arlington, Virginia. At
the hearing, both parties called
witnesses to testify and introduced
documentary and/or demonstrative
evidence. Following the hearing, both
parties submitted briefs containing their
proposed findings of fact, conclusions of
law, and argument.
On October 2, 2006, the ALJ issued
her decision. In that decision, the ALJ
concluded that Respondent’s continued
registration would be inconsistent with
the public interest and recommended
that I revoke Respondent’s registration
and deny any pending applications for
renewal or modification. ALJ Dec.
(hereinafter ALJ) at 32. Neither party
filed exceptions.
On November 13, 2006, the ALJ
forwarded the record to me for final
agency action. Having carefully
reviewed the record as a whole, I hereby
issued this decision and final order. I
adopt the ALJ’s findings of fact and
conclusions of law except as noted
herein. Furthermore, while
Respondent’s registration expired on
November 30, 2006, and Respondent
did not submit a renewal application, I
nonetheless conclude that this case is
not moot. See William R. Lockridge, 71
FR 77791, 77797 (2006). Accordingly,
while I do not adopt the ALJ’s
recommendation that Respondent’s
registration be revoked, I will review the
propriety of the immediate suspension
under section 304(a) of the Controlled
Substances Act, 21 U.S.C. 824(a), and
make the following findings.
PO 00000
Frm 00107
Fmt 4703
Sfmt 4703
30849
Findings of Fact
Respondent is a corporation, which is
owned and operated by Mr. Obi
Enemchukwu, a pharmacist, and does
business as Oviedo Discount Pharmacy
in Oviedo, Florida. ALJ at 2; ALJ Ex. at
3. Respondent held DEA Certificate of
Registration, BT2863668, which
authorized it to dispense controlled
substances in Schedules II through V,
from September 1991 until the
expiration of its registration on
November 30, 2006. ALJ Ex. 3, at 1.
Respondent last renewed its registration
on October 24, 2003. Id. I take official
notice of the fact that Respondent did
not submit a renewal application prior
to the expiration of its registration.1
Accordingly, I find that Respondent is
no longer registered with the Agency.
See 5 U.S.C. 558(c).
DEA’s 2001 Policy Statement on
Internet Prescribing and Dispensing
In April 2001, several years before the
events at issue here, DEA published in
the Federal Register a guidance
document entitled ‘‘Dispensing and
Purchasing Controlled Substances over
the Internet.’’ 66 FR 21181 (2001); see
also Gov. Ex. 18. DEA issued this
document to advise ‘‘the public
concerning the application of current
laws and regulations as they relate to
the use of the Internet for dispensing
[and] purchasing * * * controlled
substances.’’ 66 FR at 21181.
More specifically, the guidance
document advised that ‘‘[o]nly
practitioners acting in the usual course
of their professional practice may
prescribe controlled substances. * * *
A prescription not issued in the usual
course of professional practice * * * is
not considered valid. Both the
practitioner and the pharmacy have a
responsibility to ensure that only
legitimate prescriptions are written and
filled.’’ Id.
The guidance document also
discussed the legality under existing
law of prescribing controlled substances
based on an on-line questionnaire. After
noting DEA’s regulation that a
prescription for a controlled substance
is not effective unless it is ‘‘ ‘issued for
1 Under the Administrative Procedure Act (APA),
an agency ‘‘may take official notice of facts at any
stage in a proceeding—even in final decision.’’ U.S.
Dept. of Justice Attorney General’s Manual on the
Administrative Procedure Act 80 (1947) (Wm. W.
Gaunt & Sons, Inc., Reprint 1979). In accordance
with the APA and DEA’s regulations, Respondent
is ‘‘entitled on timely request to an opportunity to
show to the contrary.’’ 5 U.S.C. 556(e); see also 21
CFR 1316.59(e). To allow Respondent the
opportunity to refute this fact, Respondent may file
a motion for reconsideration within fifteen days of
service of this order which shall commence with
the mailing of the order.
E:\FR\FM\04JNN1.SGM
04JNN1
Agencies
[Federal Register Volume 72, Number 106 (Monday, June 4, 2007)]
[Notices]
[Pages 30846-30849]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-10624]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. 07-19]
CRJ Pharmacy, Inc. and YPM Total Care Pharmacy, Inc.; Revocation
of Registrations
This is a consolidated proceeding involving two pharmacies under
common ownership. On February 2, 2007, I issued an Order to Show Cause
and Immediate Suspension of DEA Certificates of Registration,
BC9458539, issued to CRJ Pharmacy, Inc., and BY9713276, issued to YPM
Total Care Pharmacy, both of Lakeland, Florida. I immediately suspended
each Respondent's registration based on my preliminary finding that
they had ``diverted and continue to divert massive amounts of
controlled substances in violation'' of federal law ``thereby creating
an imminent danger to public health or safety.'' Show Cause Order at 5.
The Show Cause Order further sought the revocation of each Respondent's
registration on the ground that its continued registration would be
``inconsistent with the public interest.'' Id. at 1 (citing 21 U.S.C.
823(f) & 824(a)(4)).
With respect to CRJ Pharmacy, the Show Cause Order alleged that it
was the fourteenth largest retail purchaser of hydrocodone-combination
products in the State of Florida, and that ``[f]rom January through
November 2006, CRJ purchased 1,416,320 dosage units of brand name and
generic hydrocodone combination products,'' a schedule III controlled
substance. Id. The Show Cause Order further alleged that on March 30,
2006, DEA investigators had inspected CRJ and determined that it filled
controlled substance orders placed through a Web site,
yourpainmanagement.com; that the orders were for persons throughout the
United States; and that the orders were authorized by only two
physicians. Id. at 2. According to the allegations, one of the
physicians was licensed to practice only in Florida; the other was
licensed only in Minnesota. Id.
The Show Cause Order further alleged that on January 22, 2007, DEA
investigators executed an administrative search warrant at CRJ and
obtained records showing that between July 3, 2006, and January 22,
2007, CRJ had ``filled approximately 19,223 controlled substance drug
orders and shipped them to customers throughout the United States.''
Id. The Show Cause Order also alleged that these prescriptions were
authorized by physicians located in Texas, Wisconsin, Puerto Rico, New
York, California, Kansas, and Florida, for persons who did not reside
in the same States as the physicians, that the prescriptions were
disproportionately for ``one or two types of highly addictive and
abused controlled substances,'' that ``CRJ filled large quantities of
prescriptions per day, per physician,'' and thus CRJ knew or should
have known that the prescriptions it dispensed ``were not issued `for a
legitimate medical purpose by an individual practitioner acting in the
usual course of his professional practice.' '' Id. at 4 (quoting 21 CFR
1306.04(a)).
The Show Cause Order alleged that CRJ's owner, Mr. Chris Larson,
had admitted to investigators that he owned bestrxcare.com. Id. at 2.
According to the Show Cause Order, Mr. Larson told investigators that
persons seeking controlled substances completed an on-line
questionnaire and then faxed their medical records to bestrxcare.com,
where they were scanned into a database for review by either a
physician or a physician's assistant (PA). Id. Mr. Larson allegedly
told investigators that if the records were ``ok,'' a physician or a PA
would then consult with the customer by telephone. Id. According to the
Show Cause Order, after the customer had paid the Web site and the
phone consultation was completed, a ``prescription'' was issued which
CRJ then downloaded from the Internet and dispensed. Id.
The Show Cause Order further alleged that a physician employed by
Larson had admitted to investigators that Larson was using his DEA
``license for pain pills.'' Id. at 3. According to the Show Cause
Order, the physician further admitted that ``he does not speak with any
of the Internet customers or their primary care physicians,'' and that
he ``does not diagnose the Internet customers or provide after care
services for the Internet customers.'' Id.
With respect to YPM, the Show Cause Order alleged that it was
dispensing controlled substances that were ordered through another Web
site, yourpainmanagment.com, which was also owned by Larson. Id. at 4.
The Show Cause Order alleged that on August 17, 2005, Larson stated to
DEA investigators that a person could order controlled substances for
pain management through this Web site by completing a form on which
they provided their name, address, billing information, general
biographic details and medical complaint. Id. Larson allegedly also
told investigators that the customers would then fax their medical
records to the Web site where they were then reviewed by a PA; if the
records appeared ``in order,'' either a physician or the PA would
conduct a telephone consultation with the customer. Id. The Show Cause
Order further alleged that during this interview, one of Larson's
employees told DEA investigators that the Web site does not order
further testing of its customers and does not contact the physicians
named on the customers' medical records. Id.
The Show Cause Order also alleged that from May 2006 through
November 2006, YPM had purchased 841,800 units of hydrocodone-
combination products. Id. Relatedly, the Show Cause Order alleged that
YPM records showed that it had dispensed 17,336 controlled substance
orders to internet customers throughout the United States and that
[[Page 30847]]
98 percent of the orders were authorized by three physicians. Id. The
Show Cause Order further alleged that two of these physicians were
licensed to practice medicine in Florida; moreover, between June 1,
2006, and January 19, 2007, the third physician, who was licensed in
Minnesota, had authorized 15,050 orders. Id. The Show Cause Order thus
alleged that YPM ``knew or should have known that the `prescriptions'
[it] dispensed were not issued `for a legitimate medical purpose by an
individual practitioner acting in the usual course of his professional
practice''' and violated federal law. Id. at 4 (quoting 21 CFR
1306.04(a)).
On February 5, 2007, both CRJ and YPM were served with the Order to
Show Cause and Immediate Suspension of Registrations. On February 22,
2007, both Respondents, who were represented by the same counsel,
requested a hearing on the allegations. The matters were assigned to
Administrative Law Judge (ALJ) Mary Ellen Bittner.
On March 12, 2007, the Government moved for summary disposition.
The basis for the Government's motion was that Respondents had closed
their businesses on February 12, 2007, and had ``transferred all
prescription records, inventory, and required DEA records to other DEA
registrants.'' Gov. Mot. for Summ. Disp. at 1. The Government's motion
further asserted that on February 27, 2007, Respondent CRJ had
surrendered its Florida Board of Pharmacy License to the Florida Board
of Pharmacy. Id. The Government further asserted that Respondent YPM
had ``signified its intent to surrender its Florida Board of Pharmacy
License in its letter to DEA dated February 22, 2007.'' Id. at 2. The
Government thus asserted that both ``Respondents are currently without
authority under Florida law to dispense controlled substances'' and
therefore are not entitled to maintain their DEA registrations. Id.
In support of its motion, the Government attached copies of letters
from both YPM (dated Feb. 27, 2007) and CRJ (dated Feb. 28, 2007) to
the DEA Miami Office; each letter advised that the pharmacy had closed,
that it was in the process of surrendering its state license, and
sought permission to act as a one-time wholesaler to sell the
controlled substances (which apparently were still in their possession)
to another pharmacy. See Appendices I & II to Gov. Mot. The Government
also attached a copy of the letter from CRJ to the Florida Board of
Pharmacy, by which it surrendered its state license. See Appendix III
to Gov. Mot. The Government's submission did not, however, include a
similar letter from YPM.
Respondent did not oppose this motion. Response to Gov. Motion for
Summ. Disp. at 1. However, on March 16, 2007, the Government had also
filed a motion to supplement the motion for summary disposition. The
Government based its motion on my decision in William R. Lockridge,
M.D., 71 FR 77,791 (2006). In Lockridge, I reviewed the propriety of an
immediate suspension in a case in which the Respondent's registration
had expired, in part, because of the collateral consequences which
attached with the issuance of the suspension. The Government thus moved
to submit several affidavits of DEA investigators to support ``the
basis for the immediate suspensions.'' Gov. Mot. to Supp. at 1.
Thereafter, on March 19, 2007, the ALJ afforded Respondents the
opportunity to respond to the Government's motion by April 2, 2007.
Subsequently, on March 22, 2007, the ALJ granted the Government's
motion for summary disposition to the extent it sought the revocation
of Respondents' DEA registrations on the ground that CRJ and YPM were
without authority under Florida law to handle controlled substances and
therefore were not entitled to maintain their DEA registrations. ALJ
Dec. at 3. The ALJ thus recommended that Respondents' registrations be
revoked. Id.
The ALJ also granted the Government's motion to supplement its
original motion for summary disposition and submit into the record the
two affidavits. The ALJ, however, also afforded Respondents the
opportunity to submit additional documents including affidavits.\1\
---------------------------------------------------------------------------
\1\ The ALJ did not, however, rule on the Government's
alternative basis for summary disposition.
---------------------------------------------------------------------------
On April 2, 2007, Respondents filed their response which vigorously
opposed the Government's motion. Respondents contended that there is
``no dispute'' that they ``can no longer hold DEA registrations.''
Response at 3. Respondents maintained, however, that the Government's
reliance on Lockridge was misplaced because in there, a full hearing
had been held and ``[m]ootness was implicated only when the
respondent's registration expired after the hearing.'' Id. at 4.
Respondents further argued that ``[t]he Government itself has
claimed that this case is moot and therefore no hearing should be
held,'' and that this precludes a ``ruling on the immediate suspension
as the Government seeks.'' Id. Respondents also contended that because
of the collateral consequences that attach with the issuance of an
immediate suspension, ``to the extent the Deputy Administrator seeks to
uphold the suspension, CRJ and YPM have a right to a hearing.'' Id.
Respondents thus maintained that granting the Government's supplemental
motion would ``violate [their] hearing rights'' because the
Government's affidavits are ``conclusory'' and cannot support the
``factual findings'' sought by the Government. Id. at 4-5 (citing 21
CFR 1316.41). Finally, Respondent contended that Lockridge ``does not,
and cannot, hold that a decision on the merits may issue after a
summary disposition.'' Id. at 5. Respondents did not, however, submit
any affidavits of their own.
Neither party filed exceptions to the ALJ's decision. Thereafter,
the ALJ forwarded the record to me for final agency action. Having
considered the record as a whole, I hereby issue this final order. I
adopt the ALJ's recommendation that each Respondent's registration be
revoked on the ground that it no longer has authority to handle
controlled substances in the State of Florida and thus is not entitled
to hold a DEA registration in that State. I further conclude that my
decision in Lockridge is not controlling and that the issue of the
validity of the immediate suspensions is now moot because each
Respondent has surrendered its Florida pharmacy license and closed its
business. Moreover, neither the Government nor Respondents have pointed
to any non-speculative collateral consequence which a ruling on the
merits of the immediate suspension order would resolve. I make the
following findings.
Findings
On April 21, 2006, Respondent YPM Total Care Pharmacy, Inc., was
issued DEA Certificate of Registration, BY9713276, as a retail
pharmacy, with an expiration date of May 31, 2009. On some date not
specified in the record, Respondent CRJ Pharmacy, Inc., was issued DEA
Certificate of Registration, BC9458539, with an expiration date of
August 31, 2008.
On February 7, 2007, DEA investigators served both YPM Total Care
Pharmacy, Inc., and CRJ Pharmacy, Inc., with the above described Order
to Show Cause and Immediate Suspension of Registration. Shortly
thereafter, on February 12, 2007, YPM closed its pharmacy. Moreover, on
February 26, 2007, YPM transferred its prescription records to another
DEA registrant, and
[[Page 30848]]
on February 28, 2007, YPM transferred its records and inventory of
controlled substances (with the Agency's approval) to that registrant.
YPM subsequently surrendered its Florida Pharmacy License. I take
official notice of the online records of the Florida Department of
Health which confirm that YPM Total Care Pharmacy has closed.\2\
---------------------------------------------------------------------------
\2\ Under the Administrative Procedure Act (APA), an agency
``may take official notice of facts at any stage in a proceeding-
even in the final decision.'' U.S. Dept. of Justice, Attorney
General's Manual on the Administrative Procedure Act 80 (1947) (Wm.
W. Gaunt & Sons, Inc., Reprint 1979). In accordance with the APA and
DEA's regulations, Respondent is ``entitled on timely request, to an
opportunity to show to the contrary.'' 5 U.S.C. 556(e); see also 21
CFR 1316.59(e). Respondent can dispute these facts by filing a
properly supported motion for reconsideration within fifteen days of
service of this order, which shall begin on the date this order is
mailed.
---------------------------------------------------------------------------
According to the record, on February 12, 2007, CRJ Pharmacy, Inc.,
also closed its pharmacy. On February 26, 2007, CJR transferred its
prescription records to another DEA registrant, and on February 28,
2007, transferred its records and inventory of controlled substances to
that registrant. CJR subsequently surrendered its Florida Pharmacy
License. I also take official notice of the online records of the
Florida Department of Health which confirm that CRJ Pharmacy has
closed.
Discussion
Under the Controlled Substances Act, a practitioner must be
currently authorized to handle controlled substances in ``the
jurisdiction in which [it] practices'' in order to maintain its DEA
registration. See 21 U.S.C. 802(21) (``[t]he term `practitioner' means
a * * * pharmacy * * * licensed, registered, or otherwise permitted, by
* * * the jurisdiction in which [it] practices * * * to * * * dispense
a controlled substance in the course of professional practice''). See
also id. section 823(f) (``The Attorney General shall register
practitioners * * * if the applicant is authorized to dispense * * *
controlled substances under the laws of the State in which [it]
practices.''). As numerous agency orders have held, ``a registrant may
not hold a DEA registration if it is without authority under the laws
of the state in which it does business.'' Bourne Pharmacy, Inc., 72 FR
18273, 18274 (2007) (quoting Oakland Medical Pharmacy, 71 FR 50100,
50102 (2006)). Accord Rx Network of South Florida, LLC, 69 FR 62,093
(2004); Wingfield Drugs, Inc., 52 FR 27,070 (1987).
Each Respondent having surrendered its State license, neither now
disputes ``that summary disposition and revocation are appropriate.''
Response to Gov. Mot. to Supplement at 3. Respondents do, however,
object to the Government's submission of the two affidavits and my
ruling on the merits of the immediate suspension.
Respondents assert that Lockridge is distinguishable because there,
a full evidentiary hearing had been held, and here, no such hearing has
been held. Respondents further argue that the validity of the immediate
suspensions is now a moot issue although they contend--inconsistently--
that they are entitled to a hearing ``before bearing the adverse
collateral consequences'' that would arise were I to issue a ruling
upholding the immediate suspension orders.
I conclude that Lockridge is not controlling and that the issue of
the validity of the immediate suspensions in this case is now moot. It
is fundamental that the issuance of an immediate suspension imposes a
deprivation of a property interest which gives rise to the protections
of the Due Process Clause. See, e.g., FDIC v. Mallen, 486 U.S. 230, 240
(1988). Subsequent events may nonetheless make clear that there is no
longer a live controversy between the parties even when the Government
has yet to provide the constitutionally required process. Cf. City News
and Novelty, Inc., v. City of Waukesha, 531 U.S. 278 (2001).
In Lockridge, I held that the proceeding was not moot
notwithstanding that the practitioner had allowed his registration to
expire following the hearing and there was no existing registration to
act upon. In so holding, I relied on several factors. These included
the collateral consequences that attached with the issuance of the
immediate suspension, in particular the harm to the practitioner's
reputation, and the additional disability imposed by the Agency's
requirement to report the suspension on any subsequent application for
a DEA registration.
I also noted that the practitioner had not moved to dismiss the
proceeding on mootness grounds and that he had submitted no evidence
showing that he ``intend[ed] to permanently cease the practice of
medicine.'' 71 FR at 77797. I thus concluded that Respondent might
apply for a new registration and seek to engage in the same practices
which had prompted the immediate suspension. Thus, it was not ``
`absolutely clear that [the practitioner's] allegedly wrongful behavior
could not reasonably be expected to recur.' '' Id. (quoting Friends of
the Earth, Inc., v. Laidlaw Env. Servs., Inc., 528 U.S. 167, 189 (2000)
(other quotations and citations omitted)).\3\
---------------------------------------------------------------------------
\3\ I also noted the extensive resources committed by both
parties in litigating the case and the potential prejudice to the
public interest were I to dismiss the proceeding without making
findings.
---------------------------------------------------------------------------
Here, by contrast, the record establishes that each Respondent has
not only surrendered its State license, but has also gone out of
business. Moreover, in contrast to the registrant in Lockridge, each
Respondent has not only engaged in affirmative acts showing that it was
ending its business activities, it has also expressly communicated
these facts to the Agency. Relatedly, neither Respondent opposes the
revocation of its registration nor seeks to litigate the validity of
the suspension orders.
Finally, neither Respondent has asserted that it plans to re-enter
the business of pharmacy at some future date. The speculative
possibility that either Respondent will seek a new registration at some
point in the future is not enough to conclude that sufficient
collateral consequences exist to render the issue of the suspension
orders' validity a live dispute. See, e.g., City News, 531 U.S. at 285;
Spencer v. Kemna, 523 U.S. 1, 16 (1998). Indeed, were either Respondent
to apply for a new registration in the future, it would nonetheless be
required to disclose on its application the revocation being ordered
below. Under these circumstances, the suspension orders impose on
Respondents no additional consequence beyond what they will be required
to disclose because of the revocations of their registrations.\4\
Accordingly, the issue is now moot.
---------------------------------------------------------------------------
\4\ Finally, in this proceeding, the Government apparently did
not place under seal the controlled substances possessed by either
Respondent at the time of the suspensions. See 21 U.S.C. 824(f).
Accordingly, title to the controlled substances is not a collateral
issue which would be resolved in this proceeding.
---------------------------------------------------------------------------
Order
Pursuant to the authority vested in me by 21 U.S.C. 824, as well as
28 CFR 0.100(b) & 0.104, I hereby order that DEA Certificate of
Registration, BC9458539, issued to CRJ Pharmacy, Inc., and DEA
Certificate of Registration, BY9713276, issued to YPM Total Care
Pharmacy, Inc., be, and they hereby are, revoked. I further order that
pending applications for renewal or modification of either registration
be, and they hereby are, denied. This order is effective July 5, 2007.
[[Page 30849]]
Dated: May 21, 2007.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. E7-10624 Filed 6-1-07; 8:45 am]
BILLING CODE 4410-09-P